Novartis AG (NYSE:NVS) had its target price lifted by analysts at Leerink Swann from $89.00 to $91.00 in a research report issued on Monday. The brokerage presently has a “market perform” rating on the stock. Leerink Swann’s target price would indicate a potential upside of 6.13% from the stock’s current price.

Several other brokerages have also recently commented on NVS. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a report on Tuesday, September 5th. BidaskClub upgraded Novartis AG from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Cowen and Company reiterated a “hold” rating on shares of Novartis AG in a report on Tuesday, July 18th. Finally, Zacks Investment Research cut Novartis AG from a “hold” rating to a “sell” rating in a report on Monday, July 10th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have issued a buy rating to the stock. Novartis AG presently has an average rating of “Hold” and a consensus target price of $85.28.

Shares of Novartis AG (NYSE:NVS) traded up 0.31% during mid-day trading on Monday, hitting $86.01. 3,928,966 shares of the company were exchanged. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90. The firm has a 50 day moving average of $85.60 and a 200 day moving average of $82.21. The company has a market capitalization of $201.51 billion, a price-to-earnings ratio of 31.40 and a beta of 0.73.

TRADEMARK VIOLATION WARNING: “Novartis AG (NVS) Price Target Increased to $91.00 by Analysts at Leerink Swann” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/23/novartis-ag-nvs-price-target-increased-to-91-00-by-analysts-at-leerink-swann.html.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Flagship Harbor Advisors LLC acquired a new position in Novartis AG in the third quarter valued at approximately $200,000. Adviser Investments LLC acquired a new position in shares of Novartis AG during the third quarter worth approximately $583,000. Augustine Asset Management Inc. acquired a new position in shares of Novartis AG during the third quarter worth approximately $735,000. Bartlett & Co. LLC raised its position in shares of Novartis AG by 1.6% during the third quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock worth $40,614,000 after purchasing an additional 7,249 shares during the period. Finally, Whittier Trust Co. raised its position in shares of Novartis AG by 0.9% during the third quarter. Whittier Trust Co. now owns 78,148 shares of the company’s stock worth $6,709,000 after purchasing an additional 730 shares during the period. 10.93% of the stock is currently owned by hedge funds and other institutional investors.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.